Literature DB >> 12798184

Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial.

Kyung-Hoon Lee1, Bryan A Ward, Zeruesenay Desta, David A Flockhart, David R Jones.   

Abstract

A sensitive and reproducible assay employing liquid-liquid extraction and high-performance liquid chromatography with fluorescence detection for the quantification of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen, and Z-4-hydroxy-N-desmethyltamoxifen in human plasma is described. The compounds and internal standard, propranolol, were separated with a cyano column and a mobile phase of acetonitrile-20 mM potassium phosphate buffer (pH 3; 35:65, v/v) then detected with fluorescence using a modified version of a method originally described by Fried and Wainer [J. Chromatogr. B 655 (1994) 261]. The coefficients of variation for the midpoint of the standard curve for each compound were less than 10%. This method was applied to a pharmacokinetic study of tamoxifen disposition in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798184     DOI: 10.1016/s1570-0232(03)00218-6

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  19 in total

1.  Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.

Authors:  Leticia B A Rangel; Jodi L Taraba; Christopher R Frei; Lon Smith; Gladys Rodriguez; John G Kuhn
Journal:  Breast Cancer Res Treat       Date:  2014-11-14       Impact factor: 4.872

Review 2.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

3.  Repression of multiple CYP2D genes in mouse primary hepatocytes with a single siRNA construct.

Authors:  Omaima Elraghy; William S Baldwin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-08-15       Impact factor: 2.416

4.  Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.

Authors:  Karen M Schweikart; Sandy R Eldridge; Stephanie L Safgren; Toufan Parman; Joel M Reid; Matthew M Ames; Matthew P Goetz; Myrtle A Davis
Journal:  Toxicol Pathol       Date:  2014-03-26       Impact factor: 1.902

5.  Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.

Authors:  Joanne S L Lim; Xiang A Chen; Onkar Singh; Yoon S Yap; Raymond C H Ng; Nan S Wong; Mabel Wong; Edmund J D Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

6.  Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis.

Authors:  Phyllis Elkins; Donna Coleman; Jason Burgess; Michael Gardner; John Hines; Brendan Scott; Michelle Kroenke; Jami Larson; Melissa Lightner; Gregory Turner; Jonathan White; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2013-07-24       Impact factor: 3.935

Review 7.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

Review 8.  Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Authors:  Christine M Walko; Howard McLeod
Journal:  Nat Clin Pract Oncol       Date:  2009-01-27

9.  Targeting tamoxifen to breast cancer xenograft tumours: preclinical efficacy of folate-attached nanoparticles based on alginate-cysteine/disulphide-bond-reduced albumin.

Authors:  A Martínez; E Muñiz; C Teijón; I Iglesias; J M Teijón; M D Blanco
Journal:  Pharm Res       Date:  2013-11-12       Impact factor: 4.200

10.  Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Authors:  Rinaa S Punglia; Harold J Burstein; Eric P Winer; Jane C Weeks
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.